Adviezen commissie BOM

Terug naar lijst
  • Auteur
  • NVMO-commissie BOM
  • Printdatum
  • 1-6-2003
  • E-pubdatum
  • 1-6-2003
  • Bron
  • Medische Oncologie

Bisfosfonaten ter voorkoming van botmetastasen

Behandeling met intraveneus toegediend bisfosfonaat lijkt aangewezen bij patiënten met röntgenologisch aantoonbare of symptomatische botmetastasen van mammacarcinoom.

Referenties

  1. www.utdol.com/application/topic
  2. Conte PF et al. ‘Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial’. J Clin Oncol 1996;14:2552-2559.
  3. Hortobagyi GN et al. ‘Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate’. J Clin Oncol 1998;16:2038-44.
  4. Theriault. RL et al. ‘Pamidronate reduces skeletal morbidity with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial’. J Clin Oncol 1999;17:846-854.
  5. Hultborn R et al. ‘Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double blind, placebo-controlled multicenter study’. Anticancer Research 1999;19:3383. 6.
  6. Cochrane database systematic review 2002;(1):CD 3474.